Search

Your search keyword '"Bijlsma, Johannes W. J."' showing total 890 results
Start Over Author "Bijlsma, Johannes W. J."
890 results on '"Bijlsma, Johannes W. J."'

3. Evaluation of the Diagnostic Performance of American College of Rheumatology, EULAR, and National Institute for Health and Clinical Excellence Criteria Against Clinically Relevant Knee Osteoarthritis:Data From the CHECK Cohort

Author

Wang, Qiuke, Runhaar, Jos, Kloppenburg, Margreet, Boers, Maarten, Bijlsma, Johannes W. J., Bierma-Zeinstra, Sita M. A., Wang, Qiuke, Runhaar, Jos, Kloppenburg, Margreet, Boers, Maarten, Bijlsma, Johannes W. J., and Bierma-Zeinstra, Sita M. A.

Abstract

ObjectiveOur objective was to evaluate the diagnostic performance of the EULAR, American College of Rheumatology (ACR), and National Institute for Health and Care Excellence (NICE) criteria by using clinical experts' diagnosis of clinically relevant knee osteoarthritis (OA) as the outcome of interest.MethodsIn a previous study, we recruited clinical experts to evaluate longitudinal (5-, 8-, and 10-year follow-up) clinical and radiographic data of symptomatic knees from the Cohort Hip and Cohort Knee (CHECK) study for the presence or absence of clinically relevant OA. In the current study, ACR, EULAR, and NICE criteria were applied to the same 5-, 8-, and 10-year follow-up data; then a knee was diagnosed with OA if fulfilling the criteria at one of the three time points (F1), two of the time points (F2), or at all three time points (F3). Using clinically relevant OA as the reference standard, the sensitivity, specificity, and positive and negative predictive values for the three criteria were assessed.ResultsA total of 539 participants for a total of 833 examined knees were included. Thirty-six percent of knees were diagnosed with clinically relevant OA by experts. Sixty-seven percent to 74% of the knees received the same diagnosis (OA or non-OA) by the three criteria sets for the different definitions (F1 to F3). EULAR consistently (F1 through F3) had the highest specificity, and NICE consistently had the highest sensitivity.ConclusionThe diagnoses only moderately overlapped among the three criteria sets. The EULAR criteria seemed to be more suitable for study enrollment (when aimed at recruiting clinically relevant OA knees), given the highest specificities. The NICE criteria, given the highest sensitivities, could be more useful for an initial diagnosis in clinical practice.

Published
2024

5. A global perspective on the challenges and opportunities in learning about rheumatic and musculoskeletal diseases in undergraduate medical education: White paper by the World Forum on Rheumatic and Musculoskeletal Diseases (WFRMD)

Author

Al Maini, Mustafa, Al Weshahi, Yousef, Foster, Helen E., Chehade, Mellick J., Gabriel, Sherine E., Saleh, Jamal Al, Al Wahshi, Humaid, Bijlsma, Johannes W. J., Cutolo, Maurizio, Lakhanpal, Sharad, Venkatramana, Manda, Pineda, Carlos, and Woolf, Anthony D.

Published
2020
Full Text
View/download PDF

7. Points to consider: EULAR–UEMS standards for the training of European rheumatologists

Author

Alunno, Alessia, primary, Avcin, Tadej, additional, Haines, Catherine, additional, Ramiro, Sofia, additional, Sivera, Francisca, additional, Badreh, Sara, additional, Baraliakos, Xenofon, additional, Bijlsma, Johannes W J, additional, Buttgereit, Frank, additional, Chaudhuri, Kaushik, additional, Da Silva, Jose A P, additional, Dudler, Jean, additional, Ferreira, Ricardo J O, additional, Gudu, Tania, additional, Hachulla, Eric, additional, Holland-Fischer, Mette, additional, Iagnocco, Annamaria, additional, Kragstrup, Tue Wenzel, additional, Nagy, György, additional, Romão, Vasco C, additional, Stones, Simon R, additional, van Onna, Marloes, additional, and Edwards, Christopher J, additional

Published
2023
Full Text
View/download PDF

9. A machine learning approach reveals features related to clinicians' diagnosis of clinically relevant knee osteoarthritis

Author

Wang, Qiuke, Runhaar, Jos, Kloppenburg, Margreet, Boers, Maarten, Bijlsma, Johannes W J, Bacardit, Jaume, Bierma-Zeinstra, Sita M A, Wang, Qiuke, Runhaar, Jos, Kloppenburg, Margreet, Boers, Maarten, Bijlsma, Johannes W J, Bacardit, Jaume, and Bierma-Zeinstra, Sita M A

Abstract

OBJECTIVES: To identify highly ranked features related to clinicians' diagnosis of clinically relevant knee OA. METHODS: General practitioners (GPs) and secondary care physicians (SPs) were recruited to evaluate 5-10 years follow-up clinical and radiographic data of knees from the CHECK cohort for the presence of clinically relevant OA. GPs and SPs were gathered in pairs; each pair consisted of one GP and one SP, and the paired clinicians independently evaluated the same subset of knees. A diagnosis was made for each knee by the GP and SP before and after viewing radiographic data. Nested 5-fold cross-validation enhanced random forest models were built to identify the top 10 features related to the diagnosis. RESULTS: Seventeen clinician pairs evaluated 1106 knees with 139 clinical and 36 radiographic features. GPs diagnosed clinically relevant OA in 42% and 43% knees, before and after viewing radiographic data, respectively. SPs diagnosed in 43% and 51% knees, respectively. Models containing top 10 features had good performance for explaining clinicians' diagnosis with area under the curve ranging from 0.76-0.83. Before viewing radiographic data, quantitative symptomatic features (i.e. WOMAC scores) were the most important ones related to the diagnosis of both GPs and SPs; after viewing radiographic data, radiographic features appeared in the top lists for both, but seemed to be more important for SPs than GPs. CONCLUSIONS: Random forest models presented good performance in explaining clinicians' diagnosis, which helped to reveal typical features of patients recognized as clinically relevant knee OA by clinicians from two different care settings.

Published
2023

10. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

Author

Bijlsma, Johannes W J, Welsing, Paco M J, Woodworth, Thasia G, Middelink, Leonie M, Pethö-Schramm, Attila, Bernasconi, Corrado, Borm, Michelle E A, Wortel, Cornelis H, ter Borg, Evert Jan, Jahangier, Z Nazira, van der Laan, Willemijn H, Bruyn, George A W, Baudoin, Paul, Wijngaarden, Siska, Vos, Petra A J M, Bos, Reinhard, Starmans, Mirian J F, Griep, Eduard N, Griep-Wentink, Joanna R M, Allaart, Cornelia F, Heurkens, Anton H M, Teitsma, Xavier M, Tekstra, Janneke, Marijnissen, Anne Carien A, Lafeber, Floris P J, and Jacobs, Johannes W G

Published
2016
Full Text
View/download PDF

11. Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation

Author

Butink, Maarten H P, primary, Webers, Casper, additional, Verstappen, Suzanne M M, additional, Falzon, Louise, additional, Betteridge, Neil, additional, Wiek, Dieter, additional, Woolf, Anthony D, additional, Stamm, Tanja A, additional, Burmester, Gerd R, additional, Bijlsma, Johannes W J, additional, Christensen, Robin, additional, and Boonen, Annelies, additional

Published
2023
Full Text
View/download PDF

17. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.

Author

Aletaha, Daniel, Kerschbaumer, Andreas, Kastrati, Kastriot, Dejaco, Christian, Dougados, Maxime, McInnes, Iain B., Sattar, Naveed, Stamm, Tanja A., Tsutomu Takeuchi, Trauner, Michael, van der Heijde, Désirée, Voshaar, Marieke, Winthrop, Kevin L., Ravelli, Angelo, Betteridge, Neil, Burmester, Gerd-Rüdiger R., Bijlsma, Johannes W. J., Bykerk, Vivian, Caporali, Roberto, and Choy, Ernest H.

Published
2023
Full Text
View/download PDF

18. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.

Author

Fragoulis, George E., Nikiphorou, Elena, Dey, Mrinalini, Zhao, Sizheng Steven, Courvoisier, Delphine Sophie, Arnaud, Laurent, Atzeni, Fabiola, Behrens, Georg MN, Bijlsma, Johannes W. J., Böhm, Peter, Constantinou, Costas A., Garcia-Diaz, Silvia, Kapetanovic, Meliha Crnkic, Lauper, Kim, Luís, Mariana, Morel, Jacques, Nagy, György, Polverino, Eva, van Rompay, Jef, and Sebastiani, Marco

Abstract

Objectives: To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).Methods: An international Task Force (TF) (22 members/15 countries) formulated recommendations, supported by systematic literature review findings. Level of evidence and grade of recommendation were assigned for each recommendation. Level of agreement was provided anonymously by each TF member.Results: Four overarching principles (OAP) and eight recommendations were developed. The OAPs highlight the need for infections to be discussed with patients and with other medical specialties, in accordance with national regulations. In addition to biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for which screening for latent tuberculosis (TB) should be performed, screening could be considered also before conventional synthetic DMARDs, glucocorticoids and immunosuppressants. Interferon gamma release assay should be preferred over tuberculin skin test, where available. Hepatitis B (HBV) antiviral treatment should be guided by HBV status defined prior to starting antirheumatic drugs. All patients positive for hepatitis-C-RNA should be referred for antiviral treatment. Also, patients who are non-immune to varicella zoster virus should be informed about the availability of postexposure prophylaxis should they have contact with this pathogen. Prophylaxis against Pneumocystis jirovecii seems to be beneficial in patients treated with daily doses >15-30 mg of prednisolone or equivalent for >2-4 weeks.Conclusions: These recommendations provide guidance on the screening and prevention of chronic and opportunistic infections. Their adoption in clinical practice is recommended to standardise and optimise care to reduce the burden of opportunistic infections in people living with AIIRD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials

Author

Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M A, Tekstra, Janneke, Jacobs, Johannes W G, Bijlsma, Johannes W J, van Laar, Jacob M, Pethö-Schramm, Attila, Borm, Michelle E A, Lafeber, Floris P J, Welsing, Paco M J, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M A, Tekstra, Janneke, Jacobs, Johannes W G, Bijlsma, Johannes W J, van Laar, Jacob M, Pethö-Schramm, Attila, Borm, Michelle E A, Lafeber, Floris P J, and Welsing, Paco M J

Published
2022

24. OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

Author

Machado, Pedro M, primary, Lawson-Tovey, Saskia, additional, Strangfeld, Anja, additional, Mateus, Elsa, additional, Hyrich, Kimme, additional, Gossec, Laure, additional, Carmona, Loreto, additional, Rodrigues, Ana, additional, Raffeiner, Bernd, additional, Duarte, Cátia, additional, Hachulla, Eric, additional, Veillard, Eric, additional, Strakova, Eva, additional, Burmester, Gerd R, additional, Yardimci, Gozde K, additional, Gómez-Puerta, José A, additional, Zepa, Julija, additional, Kearsley-Fleet, Lianne, additional, Trefond, Ludovic, additional, Cunha, Maria M, additional, Mosca, Marta, additional, Cornalba, Martina, additional, Soubrier, Martin, additional, Roux, Nicolas, additional, Brocq, Olivier, additional, Durez, Patrick, additional, Conway, Richard, additional, Goulenok, Tiphaine, additional, Bijlsma, Johannes W. J, additional, McInnes, Iain, additional, and Mariette, Xavier, additional

Published
2022
Full Text
View/download PDF

25. Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic

Author

Lauper, Kim, Bijlsma, Johannes W J, and Burmester, Gerd R

Subjects
0301 basic medicine, medicine.medical_specialty, Telemedicine, Coronavirus disease 2019 (COVID-19), Immunology, MEDLINE, Disease, Bibliometrics, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Rheumatic Diseases, Internal medicine, Pandemic, medicine, Humans, Immunology and Allergy, ddc:610, 030203 arthritis & rheumatology, SARS-CoV-2, business.industry, COVID-19, 030104 developmental biology, Annals, Family medicine, business
Abstract

The COVID-19 pandemic shattered our world, whether at home or in our professional lives. Many of our colleagues or us were in the frontlines. Family and friends turned ill. Meanwhile, researchers all around the world rushed to understand this new disease, evaluate its course and find a cure. As rheumatologists and researchers in rheumatology, we have a deep understanding of the immune system, whether in reaction to an infection or during the course of a rheumatologic disease, and its interplay with the wide range of immunomodulatory treatments available. We also need to understand how this disease impacts our patients. Therefore, since the beginning of the pandemic, the rheumatology community is at the forefront of COVID-19 related research. From the first letter on COVID-19 in March 20201 to the end of September, the Annals of the Rheumatic Diseases (ARD) have published more than 200 letters, correspondences, originals studies and other articles (figure 1). The first publication on COVID-19 in ARD by Figueroa-Parra et al ‘Are my patients with rheumatic diseases at higher risk of COVID-19?’ already illustrated the most burning questions of the rheumatology community: the potential risks of infection or severe outcome associated with the rheumatic diseases themselves or their therapy and the efficacy of antimalarial drugs in treating COVID-19.1 Other topics that were widely discussed were the drug shortage of hydroxychloroquine, the use of telemedicine and the effect of the pandemic on patients. In this brief review of ARD publications on COVID-19, we will explore how perceptions and information changed and how interests shifted from one topic to another during the last months. Figure 1 Numbers of publications about COVID-19 from March to September 2020 in the Annals of the Rheumatic Diseases by month and type. Most of the publications on COVID-19 from March 2020 to September 2020 on …

Published
2020

26. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

Author

Strehl, Cindy, Bijlsma, Johannes W J, de Wit, Maarten, Boers, Maarten, Caeyers, Nele, Cutolo, Maurizio, Dasgupta, Bhaskar, Dixon, William G, Geenen, Rinie, Huizinga, Tom W J, Kent, Alison, de Thurah, Annette Ladefoged, Listing, Joachim, Mariette, Xavier, Ray, David W, Scherer, Hans U, Seror, Raphaèle, Spies, Cornelia M, Tarp, Simon, Wiek, Dieter, Winthrop, Kevin L, and Buttgereit, Frank

Published
2016
Full Text
View/download PDF

29. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.

Author

Landewé, Robert B. M., Kroon, Féline P. B., Alunno, Alessia, Najm, Aurélie, Bijlsma, Johannes W. J., Burmester, Gerd-Rüdiger R., Caporali, Roberto, Combe, Bernard, Conway, Richard, Curtis, Jeffrey R., Elkayam, Ori, Gossec, Laure, Heijstek, Marloes W., Haupt, Lukas, lagnocco, Annamaria, Isaacs, John D., Juhász, István Ábel, Makri, Suzi, Mariette, Xavier, and Mclnnes, Iain B.

Published
2022
Full Text
View/download PDF

30. Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort

Author

Wang, Qiuke, Runhaar, Jos, Kloppenburg, Margreet, Boers, Maarten, Bijlsma, Johannes W. J., Bierma-Zeinstra, Sita M. A., Aerts-Lankhorst, N. E., Agricola, R., Bastick, A. N., van Bentveld, R. D. W., van den Berg, P. J., Bijsterbosch, J., de Boer, A., Boers, M., Bohnen, A. M., Boonen, A. E. R. C. H., Bos, P. K., Boymans, T. A. E. J., Breedveldt-Boer, H. P., Brouwer, R. W., Colaris, J. W., Damen, J., Elshout, G., Emans, P. J., Enthoven, W. T. M., Frölke, E. J. M., Glijsteen, R., van der Heide, H. J. C., Huisman, A. M., van Ingen, R. D., Jacobs, M. L., Janssen, R. P. A., Kevenaar, P. M., van Koningsbrugge, M. A., Krastman, P., Kuchuk, N. O., Landsmeer, M. L. A., Lems, W. F., van der Linden, H. M. J., van Linschoten, R., Mahler, E. A. M., van Meer, B. L., Meuffels, D. E., der Laan, W. H. Noort-van, van Ochten, J. M., van Oldenrijk, J., Pols, G. H. J., Piscaer, T. M., Vis, M., de Vries, A., Orthopaedic Biomechanics, Epidemiology and Data Science, AII - Inflammatory diseases, APH - Methodology, Rheumatology, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, General Practice, and Orthopedics and Sports Medicine

Subjects
medicine.medical_specialty, Diseases of the musculoskeletal system, Osteoarthritis, Early clinical course, Cohort Studies, Internal medicine, medicine, Humans, Stage (cooking), Generalized estimating equation, CHECK cohort, Receiver operating characteristic, business.industry, Osteoarthritis, Knee, medicine.disease, Knee/diagnostic imaging, Rheumatology, Confidence interval, Osteoarthritis, Knee/diagnostic imaging, Early Diagnosis, RC925-935, ROC Curve, Cohort, Orthopedic surgery, Disease Progression, Knee osteoarthritis, business, Research Article
Abstract

Background Early diagnosis of knee osteoarthritis (OA) is important in managing this disease, but such an early diagnostic tool is still lacking in clinical practice. The purpose of this study was to develop diagnostic models for early stage knee OA based on the first 2-year clinical course after the patient’s initial presentation in primary care and to identify whether these course factors had additive discriminative value over baseline factors. Methods We extracted eligible patients’ clinical and radiographic data from the CHECK cohort and formed the first 2-year course factors according to the factors’ changes over the 2 years. Clinical expert consensus-based diagnosis, which was made via evaluating patients’ 5- to 10-year follow-up data, was used as the outcome factor. Four models were developed: model 1, included clinical course factors only; model 2, included clinical and radiographic course factors; model 3, clinical baseline factors + clinical course factors; and model 4, clinical and radiographic baseline factors + clinical and radiographic course factors. All the models were built by a generalized estimating equation with a backward selection method. Area under the receiver operating characteristic curve (AUC) and its 95% confidence interval (CI) were calculated for assessing model discrimination. Delong’s method compared AUCs. Results Seven hundred sixty-one patients with 1185 symptomatic knees were included in this study. Thirty-seven percent knees were diagnosed as OA at follow-up. Model 1 contained 6 clinical course factors; model 2: 6 clinical and 3 radiographic course factors; model 3: 6 baseline clinical factors combined with 5 clinical course factors; and model 4: 4 clinical and 1 radiographic baseline factors combined with 5 clinical and 3 radiographic course factors. Model discriminations are as follows: model 1, AUC 0.70 (95% CI 0.67–0.74); model 2, 0.74 (95% CI 0.71–0.77); model 3, 0.77 (95% CI 0.74–0.80); and model 4, 0.80 (95% CI 0.77–0.82). AUCs of model 3 and model 4 were slightly but significantly higher than corresponding baseline-factor models (model 3 0.77 vs 0.75, p = 0.031; model 4 0.80 vs 0.76, p = 0.003). Conclusions Four diagnostic models were developed with “fair” to “good” discriminations. First 2-year course factors had additive discriminative value over baseline factors.

Published
2021

43. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, Josef S, Landewé, Robert, Breedveld, Ferdinand C, Buch, Maya, Burmester, Gerd, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cécile, Gossec, Laure, Nam, Jackie, Ramiro, Sofia, Winthrop, Kevin, de Wit, Maarten, Aletaha, Daniel, Betteridge, Neil, Bijlsma, Johannes W J, Boers, Maarten, Buttgereit, Frank, Combe, Bernard, Cutolo, Maurizio, Damjanov, Nemanja, Hazes, Johanna M W, Kouloumas, Marios, Kvien, Tore K, Mariette, Xavier, Pavelka, Karel, van Riel, Piet L C M, Rubbert-Roth, Andrea, Scholte-Voshaar, Marieke, Scott, David L, Sokka-Isler, Tuulikki, Wong, John B, and van der Heijde, Désirée

Published
2014
Full Text
View/download PDF

45. Glucocorticoids

Author

Jacobs, Johannes W. G., primary, Spies, Cornelia M., additional, Bijlsma, Johannes W. J., additional, and Buttgereit, Frank, additional

Published
2013
Full Text
View/download PDF

46. Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider

Author

Ritschl, Valentin, Stamm, Tanja A., Aletaha, D., Bijlsma, Johannes W. J., Boehm, Peter, Dragoi, Razvan, Bemt, B.J.F van den, Carmona, Loreto, Thurah, Annette de, Ritschl, Valentin, Stamm, Tanja A., Aletaha, D., Bijlsma, Johannes W. J., Boehm, Peter, Dragoi, Razvan, Bemt, B.J.F van den, Carmona, Loreto, and Thurah, Annette de

Abstract

Contains fulltext : 226798.pdf (publisher's version ) (Open Access)

Published
2020

48. 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice

Author

Ritschl, Valentin, primary, Stamm, Tanja A, additional, Aletaha, Daniel, additional, Bijlsma, Johannes W J, additional, Böhm, Peter, additional, Dragoi, Razvan Gabriel, additional, Dures, Emma, additional, Estévez-López, Fernando, additional, Gossec, Laure, additional, Iagnocco, Annamaria, additional, Marques, Andrea, additional, Moholt, Ellen, additional, Nudel, Michal, additional, van den Bemt, Bart J F, additional, Viktil, Kirsten, additional, Voshaar, Marieke, additional, de Thurah, Annette, additional, and Carmona, Loreto, additional

Published
2020
Full Text
View/download PDF

50. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis

Author

Fernandes, Linda, Hagen, Kåre B, Bijlsma, Johannes W J, Andreassen, Oyvor, Christensen, Pia, Conaghan, Philip G, Doherty, Michael, Geenen, Rinie, Hammond, Alison, Kjeken, Ingvild, Lohmander, L Stefan, Lund, Hans, Mallen, Christian D, Nava, Tiziana, Oliver, Susan, Pavelka, Karel, Pitsillidou, Irene, da Silva, José Antonio, de la Torre, Jenny, Zanoli, Gustavo, and Vliet Vlieland, Theodora P M

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results